KDM1A and acute respiratory distress syndrome: ORY-2001 (vafidemstat) is another LSD1/MAO-B dual inhibitor developed by Oryzon Genomics.239 However, its clinical studies were mainly designed for treating Alzheimer’s disease (EudraCT 2019-001436-54; ClinicalTrials.gov Identifier: NCT03867253), acute respiratory distress syndrome (ARDS) (EudraCT 2020-001618-39), multiple sclerosis (MS) (EudraCT 2017-002838-23), borderline personality disorder (ClinicalTrials.gov Identifier: NCT04932291), etc, rather than tumors.